Progyny, Inc. (NASDAQ:PGNY) Stock Has Consensus Target Price of $34.36 According to Brokerages

Shares of Progyny, Inc. (NASDAQ:PGNY) have earned a consensus rating of “Moderate Buy” from the thirteen brokerages that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $34.36.

A number of analysts recently commented on the company. KeyCorp upped their price objective on Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Citigroup reaffirmed an “outperform” rating on shares of Progyny in a research note on Tuesday, September 8th. Truist Financial lifted their target price on shares of Progyny from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Zacks Research raised Progyny from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. Finally, Citizens Jmp raised their price objective on Progyny from $31.00 to $33.00 and gave the company a “market outperform” rating in a research report on Tuesday, September 8th.

Insider Activity

In other news, Director Kevin Gordon sold 11,500 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $27.94, for a total transaction of $321,310.00. Following the sale, the director directly owned 6,792 shares of the company’s stock, valued at $189,768.48. This represents a 62.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 9.90% of the stock is owned by company insiders.

Institutional Trading of Progyny

Several hedge funds have recently made changes to their positions in the business. Public Employees Retirement System of Ohio purchased a new stake in Progyny during the 2nd quarter valued at $29,000. Nykredit A S purchased a new position in Progyny in the 2nd quarter worth about $38,000. Hantz Financial Services Inc. raised its stake in shares of Progyny by 79.4% during the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after acquiring an additional 742 shares in the last quarter. IFP Advisors Inc raised its position in Progyny by 376.0% during the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock valued at $57,000 after purchasing an additional 1,549 shares in the last quarter. Finally, Toth Financial Advisory Corp purchased a new position in shares of Progyny during the second quarter valued at $65,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Progyny Stock Performance

PGNY opened at $25.44 on Monday. The stock has a fifty day simple moving average of $27.76 and a two-hundred day simple moving average of $24.58. The company has a market cap of $1.95 billion, a price-to-earnings ratio of 27.65, a price-to-earnings-growth ratio of 1.76 and a beta of 0.99. Progyny has a 12-month low of $16.10 and a 12-month high of $33.06.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.22. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The business had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $349.05 million. During the same quarter in the prior year, the business earned $0.19 EPS. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, analysts predict that Progyny will post 1.25 EPS for the current year.

About Progyny

Progyny, Inc is a benefits management company that provides fertility and family-building solutions to employers and their employees. Its platform is designed to support individuals and couples pursuing fertility treatment, including in vitro fertilization, egg freezing, donor services, gestational surrogacy and adoption.

The company’s services combine access to a network of fertility specialists with personalized guidance, care coordination and treatment support. Progyny also offers pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.